Author:
Brown John V.,Rettenmaier Mark A.,Dillman Robert A.,Birk Connie L.,Culkin Kathleen,Micha John Paul
Subject
Obstetrics and Gynaecology,Oncology
Reference15 articles.
1. Ozols, R, F, Rubin, S, C, Thomas, G, M, Robboy, S, J, Epithelial Ovarian Cancer, Principles and Practice of Gynecologic Oncology, Philadelphia, PA, 1997
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996
3. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion;Eisenhauer;J Clin Oncol,1994
4. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer;Alberts;J Clin Oncol,1992
5. Cisplatin-cyclophosphamide versus carboplatin-cycleophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada clinical Trials Group;Swenerton;J Clin Oncol,1992
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma;Cancer Chemotherapy and Pharmacology;2013-05-10
2. Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer;International Journal of Gynecologic Cancer;2013-03
3. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum;International Journal of Gynecologic Cancer;2008
4. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer;International Journal of Gynecological Cancer;2007-07
5. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer;Gynecologic Oncology;2005-01